Claims for Patent: 12,534,530

Summary for Patent: 12,534,530

Title:	Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Abstract:	The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Inventor(s):	Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
Assignee:	Pfizer Corp SRL , Merck Sharp and Dohme LLC
Application Number:	US17/725,240
Patent Claims:	1. A method for treating a renal cell carcinoma (RCC) in an individual comprising administering to the individual a combination therapy which comprises pembrolizumab and axitinib, wherein the individual has not been previously treated for RCC, wherein axitinib is administered at a starting dose of 5 mg twice daily (BID), and wherein if the individual tolerates axitinib with no drug-related grade >2 adverse events for two consecutive weeks, the dose of axitinib is then increased to a maximum dose of 10 mg BID. 2. The method of claim 1, wherein the individual is an adult human. 3. The method of claim 1, wherein the RCC comprises a solid tumor. 4. The method of claim 1, wherein the RCC is advanced renal cell carcinoma. 5. The method of claim 1, wherein pembrolizumab is administered at a dose selected from the group consisting of 1 mg/kg every three weeks (Q3W), 2 mg/kg Q3W, and 200 mg Q3W. 6. The method of claim 5, wherein pembrolizumab is administered at a dose of 2 mg/kg Q3W. 7. The method of claim 5, wherein pembrolizumab is administered at a dose of 200 mg Q3W. 8. The method of claim 1, wherein the dose of axitinib is increased to 7 mg BID. 9. A method for treating a renal cell carcinoma (RCC) in an individual comprising administering to the individual a combination therapy which comprises pembrolizumab and axitinib, wherein the individual has not been previously treated for RCC, wherein axitinib is administered at a starting dose of 5 mg BID, and wherein if the dose combination is not tolerated by the individual, the dose of axitinib is then reduced to a minimum dose of 3 mg BID. 10. The method of claim 9, wherein the individual is an adult human. 11. The method of claim 9, wherein the RCC comprises a solid tumor. 12. The method of claim 9, wherein the RCC is advanced renal cell carcinoma. 13. The method of claim 9, wherein pembrolizumab is administered at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W, and 200 mg Q3W. 14. The method of claim 13, wherein pembrolizumab is administered at a dose of 2 mg/kg Q3W. 15. The method of claim 13, wherein pembrolizumab is administered at a dose of 200 mg Q3W. 16. The method of claim 2, wherein the individual has controlled hypertension. 17. The method of claim 4, wherein the advanced renal cell carcinoma in the individual is predominantly clear-cell subtype with primary tumor resected. 18. The method of claim 10, wherein the individual has controlled hypertension. 19. The method of claim 12, wherein the advanced renal cell carcinoma in the individual is predominantly clear-cell subtype with primary tumor resected.